Analyst Price Target is $3.00
▲ +792.33% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for TransCode Therapeutics in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 792.33% upside from the last price of $0.34.
Current Consensus is
Buy
The current consensus among 1 contributing investment analysts is to buy stock in TransCode Therapeutics. This Buy consensus rating has held steady for over two years.
TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
Read More
